ArticleCancer chemotherapy and pharmacology2016

Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphoma.

Ayana Tomono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.